Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Open Label Study Investigating the Efficacy of the BiTE Antibody Blinatumomab Versus Standard of Care Chemotherapy in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) (TOWER Study)

Next Previous
Trial Profile

A Phase 3, Randomized, Open Label Study Investigating the Efficacy of the BiTE Antibody Blinatumomab Versus Standard of Care Chemotherapy in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) (TOWER Study)

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 15 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Blinatumomab (Primary) ; Alkylating agents; Anthracyclines; Asparaginase; Clofarabine; Cytarabine; Etoposide; Fludarabine; Granulocyte colony-stimulating factors; Idarubicin; Methotrexate; Pegaspargase; Steroids; Vinca alkaloids
  • Indications Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms TOWER
  • Sponsors Amgen

Most Recent Events

  • 01 Nov 2023 Results published in the Cancer Immunology Immunotherapy
  • 06 Oct 2023 Results of retrospective pooled analysis of 3 clinical trials( ZUMA-3, INO-VATE, and TOWER)estimating the relative treatment effects of brexu-cel versus inotuzumab ozogamicin (InO), blinatumomab (blina), and chemotherapies for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Adult Patients, published in the Advances in Therapy.
  • 21 Jun 2023 According to an Amgen media release, based on additional data from two phase III trials, U.S. Food and Drug Administration (FDA) has approved supplemental Biologics License Application (sBLA) for BLINCYTO (blinatumomab) for the treatment of adults and pediatric patients with CD19-positive B-cell precursor acute lymphoblastic in first or second complete remission with minimal residual disease greater than or equal to 0.1%.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top